ArticleScientific reports2025
In vitro assessment of Moringa Oleifera leaf extract's protective impact on fibroblast cell line (WI-38) exposed to electronic cigarette liquid.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Moringa oleifera (MO), a medicinal herb, has been studied in recent decades for its diverse range of biological activities. Several studies have revealed that MO leaf extract (MOLE) possesses cytoprotective properties, while other studies have reported anti-proliferative potential. This study was conducted to assess the potential effect of MOLE on electronic cigarette liquid (EC e-liquid) treated human lung fibroblast cell line (WI-38). An MTT assay was performed to investigate the potential effect of EC e-liquid and MOLE on cell viability and determine the cytotoxic concentration (CC50) in WI-38 cells. Cells were treated with 190.2 µg/mL of EC e-liquid (EC group) and 33.2 µg/mL of EC e-liquid and MOLE (EC + MOLE group) for 24 h. Analysis of apoptosis and cell cycle was performed using flow cytometric assay. Moreover, the expression of apoptosis-related proteins Bax and Bcl2 was measured using ELISA.Our findings revealed that MOLE demonstrated a cytotoxic effect on EC e-liquid treated WI-38 cells through induction of apoptosis via up-regulation of Bax and down-regulation of Bcl2. Additionally, MOLE induced cell cycle arrest at the S phase. Overall, these findings indicate that MOLE is an inefficient cytoprotective agent against EC e-liquid cytotoxicity; nonetheless, it exerts a cytotoxic effect, suggesting a promising role as a valuable anti-proliferative agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.